You have 9 free searches left this month | to do more

nivolumab

Nivolumab is a drug used to treat Melanoma, Metastatic Melanoma, Renal Cell Carcinoma, and other conditions. Nivolumab is being actively studied in 635 studies and prior, has been studied in 83.

Top SponsorsTop SitesTop Investigators
Bristol-Myers SquibbLocal InstitutionIvan S Moiseev
National Cancer Institute (NCI)Memorial Sloan Kettering Cancer CenterInna Chen, MD
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsDana Farber Cancer InstituteTheodore Sunki Hong
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Recruiting
  • Melanoma Stage III
  • Melanoma
  • Philadelphia, Pennsylvania
    Abramson Cancer Center, University of Pennsylvania
2021-05-14
May 14, 2021
D
Recruiting
  • Melanoma
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
2021-11-16
Nov 16, 2021
A
Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Whittier, California
    Innovative Clinical Research Institute
2021-12-02
Dec 2, 2021
I
Not yet recruiting
  • Muscle-Invasive Bladder Carcinoma
  • Nivolumab + Nab-paclitaxel
  • Nivolumab
  • Milan, MI, Italy
    Genitourinary Medical Oncology - IRCCS San Raffaele Hospital and
2021-05-03
May 3, 2021
K
Completed
  • Advanced and Metastatic Solid Tumor
  • Kashiwa, Chiba, Japan
    NationalCCHE
2021-04-23
Apr 23, 2021
C
Active, not recruiting
  • Glioblastoma
  • Nivolumab
  • +2 more
  • Boston, Massachusetts
  • +1 more
2021-05-21
May 21, 2021
D
Active, not recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-07-22
Jul 22, 2021
N
Active, not recruiting
  • Non-Small Cell Lung Cancer
  • Singapore, Singapore
  • +2 more
2021-04-27
Apr 27, 2021
C
Not yet recruiting
  • Gastric Cancer
  • Chemotherapy Effect
  • Nivolumab plus SOX
  • +2 more
  • (no location specified)
2021-08-15
Aug 15, 2021
B
Active, not recruiting
  • Solid Tumors
  • Nivolumab
  • Guangzhou, Guangdong, China
  • +1 more
2021-09-17
Sep 17, 2021
T
Recruiting
  • Cutaneous Squamous Cell Carcinoma
  • Amsterdam, Noord Holland, Netherlands
    NKI-AVL
2020-11-05
Nov 5, 2020
N
Active, not recruiting
  • Ann Arbor Stage III Lymphoma
  • +4 more
  • Bethesda, Maryland
  • +2 more
2021-08-27
Aug 27, 2021
T
Recruiting
  • Breast Cancer
  • Amsterdam, Netherlands
    NKI-AVL
2021-09-28
Sep 28, 2021
V
Active, not recruiting
  • Oral Cavity Squamous Cell Carcinoma
  • Nivolumab
  • Amsterdam, Noord-Holland, Netherlands
    VU University medical center
2021-10-06
Oct 6, 2021
D
Active, not recruiting
  • Thyroid Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2021-07-15
Jul 15, 2021
B
Active, not recruiting
  • Cancer
  • Hackensack, New Jersey
    Hackensack University Medical Center
2021-09-13
Sep 13, 2021
S
Recruiting
  • Microsatellite Stable (MSS) Colorectal Adenocarcinomas
  • Colorectal Adenocarcinoma
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
2021-08-18
Aug 18, 2021
M
Active, not recruiting
  • Bladder Cancer
  • Melanoma
  • Nivolumab
  • Nivolumab plus Ipilimumab
  • Farmington, Connecticut
  • +4 more
2021-10-01
Oct 1, 2021
R
Active, not recruiting
  • Renal Cell Carcinoma
  • Washington, District of Columbia
  • +1 more
2021-07-26
Jul 26, 2021
S
Recruiting
  • Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy
  • MSI-H Tumors
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
2021-08-18
Aug 18, 2021
Y
Not yet recruiting
  • Locally Advanced Nasopharyngeal Carcinoma
  • Nivolumab
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
2021-05-26
May 26, 2021
T
Withdrawn
  • Nasopharyngeal Carcinoma
  • Nivolumab
  • (no location specified)
2021-04-28
Apr 28, 2021
D
Recruiting
  • Ovarian Cancer
  • Nivolumab
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2021-06-21
Jun 21, 2021
A
Recruiting
  • Metastatic Melanoma
  • Hypofractionated Radiation Therapy (HFRT)
  • +2 more
  • Philadelphia, Pennsylvania
    Abramson Cancer Center
2021-03-30
Mar 30, 2021